NATCO Pharma has said that the US Court of Appeals for the Federal Circuit ruling, has reversed a district court's finding related to Teva's US Patent for Copaxone.
This would essentially mean that NATCO could launch the generic Copaxone - through its
marketing partner - Mylan Inc., during May 2014, subject to FDA approval. Copaxone (Glatiramer Acetate) is used in the treatment of relapsing-remitting multiple sclerosis.
The product is estimated to have clocked revenues, in USA, of about US $3.45 Billion during 2012.
Shares in Natco which closed at Rs 491 on Friday, may receive a boost when markets re-open for trading on Monday.